跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AN-7
首页
药物
AN-7
AN-7
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Method for preparing an enantiomerically enriched form of 3-(2-chlorothiazol-5-yl)-8-methyl-7-oxo-6-phenyl-2,3-dihydrothiazolo[3,2-ajpyrimidin-4-ium-5-olate
US 12559507 B2
申请人: BASF SE
优先权: 2021
CN
EP
US
WO
6 件公开
METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE
EP 4032894 A1
申请人: BASF SE
优先权: 2021
CN
EP
US
WO
6 件公开
NPY Y5 antagonist
US 7265130 B2
申请人: SHIONOGI & CO
优先权: 1999
CN
US
6 件公开
CONJUGATES OF AN IL-7 MOIETY AND AN POLYMER
EP 3285799 A4
申请人: NEKTAR THERAPEUTICS
优先权: 2015
CN
EP
US
WO
5 件公开
Use of luteolin-7-O-glucoside or luteolin-7-O-glucuronide in preparation of medicine for eye injuries
US 12383573 B2
申请人: BEIJING CHENGYI INVEST CO LTD
优先权: 2019
CN
EP
US
WO
5 件公开
STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-2-YL)-1-(1H-INDOL-3-YL)-6,7-DIHYDRO-3H-OXAZOL[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTITUMOR AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR
EP 4001282 A4
申请人: BIOLAB SANUS FARMACEUTICA LTDA
优先权: 2019
CN
EP
US
WO
5 件公开
METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND AN IMMUNE CHECKPOINT INHIBITOR
EP 3880231 A1
申请人: NEOIMMUNETECH INC
优先权: 2018
CN
EP
US
WO
4 件公开
FORMULATIONS COMPRISING AN IMMUNOGLOBULIN-LIKE TRANSCRIPT 7 (ILT7)-BINDING PROTEIN
EP 4562039 A1
申请人: VIELA BIO INC
优先权: 2022
CN
EP
US
WO
4 件公开
Composition, in particular cosmetic, containing 7-hydroxy DHEA and/or 7-keto DHEA and at least an isoflavonoid
US 6852326 B2
申请人: OREAL
优先权: 2000
EP
US
WO
4 件公开
METHOD FOR INCREASING LYMPHOCYTE COUNT BY USING IL-7 FUSION PROTEIN IN TUMORS
EP 4025241 A4
申请人: GENEXINE INC
优先权: 2019
CN
EP
US
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈